Apelin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy

Clinical and Experimental Rheumatology

Volumn 31, Issue 4, 2013, Pages 532-537

  Genre, F ^a   Miranda Filloy, J A ^b   Lopez Mejias R ^a   Carnero Lopez B ^c   Ochoa, R ^a   Rueda, J ^a   Gonzalez Juanatey C ^b   Blanco, R ^a   Llorca, J ^d   Gonzalez Gay M A ^a  

^a Epidemiology Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases   (Spain)

^b HOSPITAL XERAL CALDE   (Spain)

^c HOSPITAL EL BIERZO   (Spain)

^d UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

Ankylosing spondylitis; Anti TNF antibody infliximab; Apelin; Atherosclerosis; Inflammation

Indexed keywords

ADIPONECTIN; APELIN; C REACTIVE PROTEIN; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INFLIXIMAB; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NAPROXEN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; NONSTEROID ANTIINFLAMMATORY AGENT; RESISTIN; TRIACYLGLYCEROL;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL FEATURE; CORRELATION ANALYSIS; DEMOGRAPHY; DIASTOLIC BLOOD PRESSURE; DISEASE ACTIVITY; DISEASE DURATION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; INFLAMMATION; MALE; METABOLIC SYNDROME X; OBESITY; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

ADIPOKINES; ADIPOSE TISSUE; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ATHEROSCLEROSIS; DIABETES MELLITUS; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84883577240     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. AZEVEDO VF, PECOITS-FILHO R: Atherosclerosis and endothelial dysfunction in patients with ankylosing spondylitis. Rheumatol Int 2010; 30: 1411-6.
2. CAPKIN E, KIRIS A, KARKUCAK M et al.: Joint Investigation of effects of different treatment modalities on structural and functional vessel wall properties in patients with ankylosing spondylitis. Bone Spine 2011; 78: 378-82.
3. GONZALEZ-JUANATEY C, VAZQUEZ-RODRIGUEZ TR, MIRANDA-FILLOY JA et al.: The high prevalence of subclinical atherosclerosis in patients with ankylosing spondylitis without clinically evident cardiovascular disease. Medicine (Baltimore) 2009; 88: 358-65.
4. PETERS MJ, van EIJK IC, SMULDERS YM et al.: Signs of accelerated preclinical atherosclerosis in patients with ankylosing spondylitis. J Rheumatol 2010; 37: 161-6.
5. BODNÁR N, KEREKES G, SERES I et al.: Assessment of subclinical vascular disease associated with ankylosing spondylitis. J Rheumatol 2011; 38: 723-9.
6. PETERS MJ, VISMAN I, NIELEN MM et al.: Ankylosing spondylitis: a risk factor for myocardial infarction? Ann Rheum Dis 2010; 69: 579-81.
7. MIRANDA-FILLOY JA, LÓPEZ-MEJIAS R, GENRE F et al.: Adiponectin and resistin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy. Clin Exp Rheumatol (in press)
8. D'ANGELO S, PALAZZI C, CANTINI F et al.: Etanercept in spondyloarthopathies. Part II: safety and pharmacoeconomic issues. Clin Exp Rheumatol 2011; 29: 865-70.
9. PALAZZI C, D'ANGELO S, CANTINI F et al.: Etanercept in spondyloarthropathies. Part I: current evidence of efficacy. Clin Exp Rheumatol 2011; 29: 858-64.
10. HELDMANN F, BRANDT J, van der HORSTBRUINSMA IE et al.: The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab. Clin Exp Rheumatol 2011; 29: 672-80.
11. MIRANDA-FILLOY JA, LLORCA J, CARNEROLÓPEZ B, GONZÁLEZ-JUANATEY C, BLANCO R, GONZÁLEZ-GAY MA: TNF-α antagonist therapy improves insulin sensitivity in non-diabetic ankylosing spondylitis patients. Clin Exp Rheumatol 2012; 30: 850-5.
12. SYNGLE A, VOHRA K, SHARMA A, KAUR L: Endothelial dysfunction in ankylosing spondylitis improves after tumor necrosis factoralpha blockade. Clin Rheumatol 2010; 29: 763-70.
13. KIDOYA H, TAKAKURA N: Biology of the apelin-APJ axis in vascular formation. J Biochem 2012; 152: 125-31.
14. TASCI I, DOGRU T, NAHARCI I et al.: Plasma apelin is lower in patients with elevated LDL-cholesterol. Exp Clin Endocrinol Diabetes 2007; 115: 428-32.
15. MALYSZKO J, MALYSZKO JS, PAWLAK K, MYSLIWIEC M: Visfatin and apelin, new adipocytokines, and their relation to endothelial function in patients with chronic renal failure. Adv Med Sci 2008; 53: 32-6.
16. van der LINDEN S, VALKENBURG HA, CATS A: Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 361-8.
17. VIS M, NURMOHAMED MT, WOLBINK G et al.: Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. J Rheumatol 2005; 32: 252-5.
18. GONZALEZ-GAY MA, GARCIA-UNZUETA MT, GONZALEZ-JUANATEY C et al.: Anti- TNF-αlpha therapy modulates resistin in patients with rheumatoid arthritis. Clin Exp Rheumatol 2008; 26: 311-6.
19. GONZALEZ-GAY MA, GARCIA-UNZUETA MT, De MATIAS JM et al.: Influence of anti- TNF-αlpha infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006; 24: 373-9.
20. BRAUN J, van den BERG R, BARALIAKOS X et al.: 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011; 70: 896-904.
21. GARRETT S, JENKINSON T, KENNEDY LG, WHITELOCK H, GAISFORD P, CALIN A: A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21: 2286-91.
22. Di FRANCO M, SPINELLI FR, METERE A et al.: Serum levels of asymmetric dimethylarginine and apelin as potential markers of vascular endothelial dysfunction in early rheumatoid arthritis. Mediators Inflamm 2012; 2012:347268. doi: 10.1155/2012/347268.
23. KUBA K, ZHANG L, IMAI Y et al.: Impaired heart contractility in Apelin gene-deficient mice associated with aging and pressure overload. Circ Res 2007 Aug; 101: e32-42.
24. GOETZE JP, REHFELD JF, CARLSEN J et al.: Apelin: a new plasma marker of cardiopulmonary disease. Regul Pept 2006; 133: 134-8.
25. LI Z, BAI Y, HU J: Reduced apelin levels in stable angina. Intern Med 2008; 47: 1951-5.
26. BOUCHER J, MASRI B, DAVIAUD D et al.: Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology 2005; 146: 1764-71.
27. LI L, YANG G, LI Q et al.: Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects. Exp Clin Endocrinol Diabetes 2006; 114: 544-8.
28. ERDEM G, DOGRU T, TASCI I, SONMEZ A, TAPAN S: Low plasma apelin levels in newly diagnosed type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2008; 116: 289-92.
29. FERRAZ-AMARO I, ARCE-FRANCO M, MUÑIZ J et al.: Systemic blockade of TNF-α does not improve insulin resistance in humans. Horm Metab Res 2011; 43: 801-8.